JP2011520793A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520793A5
JP2011520793A5 JP2011507463A JP2011507463A JP2011520793A5 JP 2011520793 A5 JP2011520793 A5 JP 2011520793A5 JP 2011507463 A JP2011507463 A JP 2011507463A JP 2011507463 A JP2011507463 A JP 2011507463A JP 2011520793 A5 JP2011520793 A5 JP 2011520793A5
Authority
JP
Japan
Prior art keywords
alk1
composition
fusion protein
seq
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011507463A
Other languages
English (en)
Japanese (ja)
Other versions
JP5719766B2 (ja
JP2011520793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/002699 external-priority patent/WO2009134428A2/en
Publication of JP2011520793A publication Critical patent/JP2011520793A/ja
Publication of JP2011520793A5 publication Critical patent/JP2011520793A5/ja
Application granted granted Critical
Publication of JP5719766B2 publication Critical patent/JP5719766B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011507463A 2008-05-02 2009-05-01 血管新生および周皮細胞組成物を調節するための方法および組成物 Expired - Fee Related JP5719766B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5016808P 2008-05-02 2008-05-02
US61/050,168 2008-05-02
US14413109P 2009-01-12 2009-01-12
US61/144,131 2009-01-12
PCT/US2009/002699 WO2009134428A2 (en) 2008-05-02 2009-05-01 Methods and compositions for modulating angiogenesis and pericyte composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014237666A Division JP6194302B2 (ja) 2008-05-02 2014-11-25 血管新生および周皮細胞組成物を調節するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2011520793A JP2011520793A (ja) 2011-07-21
JP2011520793A5 true JP2011520793A5 (https=) 2012-06-21
JP5719766B2 JP5719766B2 (ja) 2015-05-20

Family

ID=41055305

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011507463A Expired - Fee Related JP5719766B2 (ja) 2008-05-02 2009-05-01 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2014237666A Expired - Fee Related JP6194302B2 (ja) 2008-05-02 2014-11-25 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2017037131A Withdrawn JP2017101068A (ja) 2008-05-02 2017-02-28 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2019171838A Withdrawn JP2019210298A (ja) 2008-05-02 2019-09-20 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2021144016A Pending JP2021183652A (ja) 2008-05-02 2021-09-03 血管新生および周皮細胞組成物を調節するための方法および組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014237666A Expired - Fee Related JP6194302B2 (ja) 2008-05-02 2014-11-25 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2017037131A Withdrawn JP2017101068A (ja) 2008-05-02 2017-02-28 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2019171838A Withdrawn JP2019210298A (ja) 2008-05-02 2019-09-20 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2021144016A Pending JP2021183652A (ja) 2008-05-02 2021-09-03 血管新生および周皮細胞組成物を調節するための方法および組成物

Country Status (11)

Country Link
US (4) US8158584B2 (https=)
EP (2) EP3398966A1 (https=)
JP (5) JP5719766B2 (https=)
KR (8) KR20180029111A (https=)
CN (2) CN105963695A (https=)
AU (5) AU2009241755B2 (https=)
BR (1) BRPI0911853A8 (https=)
CA (1) CA2723449C (https=)
MX (2) MX391905B (https=)
TW (3) TWI672151B (https=)
WO (1) WO2009134428A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
KR20170012582A (ko) 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20100090683A (ko) 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
TWI672151B (zh) * 2008-05-02 2019-09-21 艾西利羅製藥公司 調節血管新生與周圍細胞組成的方法與組合物
CA2724525A1 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
AU2013214779A1 (en) * 2012-02-02 2014-09-04 Acceleron Pharma Inc. ALK1 antagonists and their uses in treating renal cell carcinoma
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA2921805C (en) * 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
CN107849114B (zh) * 2015-04-06 2021-08-20 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
US10227392B2 (en) * 2015-04-06 2019-03-12 Acceleron Pharma Inc. ALK7:ActRIIB heteromultimers and uses thereof
CN110317264B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物
HRP20210694T1 (hr) 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
US11292846B2 (en) * 2017-11-02 2022-04-05 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
CN114028541A (zh) * 2021-05-21 2022-02-11 中山大学 Gdf2在制备改善肿瘤异常血管的药物中的用途
WO2024153115A1 (zh) * 2023-01-18 2024-07-25 开拓药业(广东)有限公司 抗alk-1抗体及其用途
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
AU5541094A (en) 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
KR950704485A (ko) 1992-11-17 1995-11-20 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP0845006A2 (en) 1995-08-14 1998-06-03 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
ES2169864T3 (es) 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
EP1071765A4 (en) 1998-03-13 2003-01-15 Ludwig Inst Cancer Res Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US20030012792A1 (en) 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7077836B2 (en) 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
AU2001283108A1 (en) 2000-08-03 2002-02-18 The University Of Utah Research Foundation Manipulation of arterial-venous identity
DE10043481A1 (de) 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
KR101072867B1 (ko) 2001-10-31 2011-10-17 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
WO2003064628A2 (en) 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
EP1534737A4 (en) 2002-04-29 2007-10-31 Univ Saint Louis PEPTIDANTAGONISTS OF MEMBERS OF THE TGF BETA FAMILY AND THEIR THERAPEUTIC APPLICATION
WO2004003163A2 (en) 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
AU2003287444A1 (en) 2002-10-31 2004-05-25 The General Hospital Corporation Repairing or replacing tissues or organs
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005044849A2 (en) 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
WO2005116850A2 (en) 2004-01-27 2005-12-08 Compugen Ltd. Differential expression of markers in ovarian cancer
US7101618B2 (en) * 2004-05-07 2006-09-05 3M Innovative Properties Company Article comprising fluorochemical surface layer
US7741284B2 (en) 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
US7897581B2 (en) 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
CA2621371C (en) * 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007143023A1 (en) 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
KR20170012582A (ko) * 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20100090683A (ko) * 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
TWI672151B (zh) * 2008-05-02 2019-09-21 艾西利羅製藥公司 調節血管新生與周圍細胞組成的方法與組合物
CA2724525A1 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof

Similar Documents

Publication Publication Date Title
JP2011520793A5 (https=)
JP2010508816A5 (https=)
US11851493B2 (en) Trispecific antagonists
AU2019232838B2 (en) Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
US20170002060A1 (en) Polynucleotides for the in vivo production of antibodies
JP2017101068A5 (https=)
CN105612175A (zh) 基于IL-15和IL-15Rαsushi结构域的调节因子
EA033359B1 (ru) Комбинация леналидомида и полипептидной конструкции и ее применение
EP3092250A1 (en) Polynucleotides for the in vivo production of antibodies
KR20140112497A (ko) 뇌혈관 장벽을 통한 치료학적 분자의 수송 개선법
US20090304691A1 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
US20230235073A1 (en) Anti-cd36 antibodies and their use to treat cancer
WO2017135791A1 (en) Anti-c-met antibodies and uses thereof
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
US20220017600A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
TW202400217A (zh) 用神經調節蛋白－１融合蛋白治療纖維化及心律不整的方法
TW201642904A (zh) 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
HK40115251A (zh) 用神经调节蛋白-1融合蛋白治疗纤维化及心律失常的方法
CN118922437A (zh) 用神经调节蛋白-1融合蛋白治疗纤维化及心律失常的方法
HK1229690A1 (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
HK1229690A (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage